Who are Norepinephrine (Levophed)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Epinephrine concentration of 1:500000, Northera, METYROSINE, Demser, Dopamine Hydrochloride, Raunormin.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/norepinephrine-levophed.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Norepinephrine (Levophed) — Competitive Intelligence Brief

Norepinephrine (Levophed) (Norepinephrine (Levophed)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Catecholamine; sympathomimetic amine. Area: Cardiovascular.

marketed Catecholamine; sympathomimetic amine Alpha-1 adrenergic receptor; alpha-2 adrenergic receptor; beta-1 adrenergic receptor Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Norepinephrine (Levophed) (Norepinephrine (Levophed)) — University of Louisville. Norepinephrine is a catecholamine that binds to alpha and beta adrenergic receptors to increase blood pressure and heart rate.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Norepinephrine (Levophed) TARGET	Norepinephrine (Levophed)	University of Louisville	marketed	Catecholamine; sympathomimetic amine	Alpha-1 adrenergic receptor; alpha-2 adrenergic receptor; beta-1 adrenergic receptor
Epinephrine concentration of 1:500000	Epinephrine concentration of 1:500000	Al-Azhar University	phase 3	Catecholamine; alpha and beta-adrenergic agonist	Alpha-1 adrenergic receptor; Alpha-2 adrenergic receptor; Beta-1 adrenergic receptor; Beta-2 adrenergic receptor
Northera	DROXIDOPA	Lundbeck Na Ltd	marketed	Catecholamine	Muscarinic acetylcholine receptor M1	2014-01-01
METYROSINE	METYROSINE		marketed	Catecholamine Synthesis Inhibitor [EPC]		1979-01-01
Demser	metirosine	Aton Pharma Vpna	marketed	Catecholamine Synthesis Inhibitor [EPC]	Tyrosine 3-monooxygenase	1979-01-01
Dopamine Hydrochloride	DOPAMINE		marketed	Catecholamine	D(1A) dopamine receptor	1974-01-01
Raunormin	DESERPIDINE		marketed	Catecholamine-depleting Sympatholytic	Synaptic vesicular amine transporter	1957-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Catecholamine; sympathomimetic amine class)

Hassan II University · 1 drug in this class
Hopital Charles Nicolle · 1 drug in this class
University of California, Davis · 1 drug in this class
University of Louisville · 1 drug in this class
University of Sao Paulo · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Norepinephrine (Levophed) — Competitive Intelligence Brief. https://druglandscape.com/ci/norepinephrine-levophed. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab